With the advancement of early detection tools for prostate cancer and ability to better localize disease, there has been increased interest in focal or targeted therapies that carry less morbidity than traditional whole-gland treatments. The Sonablate® high-intensity focused ultrasound (HIFU) device has Food and Drug Administration (FDA) 510(K) clearance in the United States for ablation of prostate tissue. HIFU utilizes an ultrasound (US) transducer that focuses US beams on a preset point as much as 4 cm from the energy source without injuring intervening tissue. The Sonablate system guides the surgeon step-by-step to perform effective ablation of a target lesion. The surgeon can assess treatment effect with tissue change monitoring, and care is taken to prevent rectal wall injury. We believe hemiablation is the most favorable focal HIFU treatment to optimize cancer control and minimize the side effects associated with whole gland therapy. We recommend considering HIFU ablation as an extension of active surveillance rather than definitive treatment. Further research on long-term oncologic and functional outcomes is warranted.

中文翻译：

---

前列腺的焦点高强度聚焦超声消融。

随着前列腺癌早期检测工具的进步以及更好地定位疾病的能力，人们对与传统全腺体治疗相比发病率更低的病灶或靶向治疗越来越感兴趣。Sonablate® 高强度聚焦超声 (HIFU) 设备在美国获得食品和药物管理局 (FDA) 510(K) 许可，可用于前列腺组织消融。HIFU 使用超声 (US) 换能器，将超声束聚焦在距能量源 4 厘米的预设点上，而不会伤害介入组织。Sonablate 系统逐步指导外科医生对目标病灶进行有效消融。外科医生可以通过组织变化监测来评估治疗效果，并注意防止直肠壁损伤。我们相信半消融是最有利的局部 HIFU 治疗，以优化癌症控制并最大限度地减少与全腺体治疗相关的副作用。我们建议考虑将 HIFU 消融作为主动监测的延伸，而不是确定性治疗。有必要对长期肿瘤学和功能结果进行进一步研究。